These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25751329)

  • 1. Relapse in psoriasis with two different tapering regimens of methotrexate: a randomized open-label controlled study.
    Singh SK; Rai T
    Indian J Dermatol Venereol Leprol; 2015; 81(2):144-7. PubMed ID: 25751329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
    Dogra S; Krishna V; Kanwar AJ
    Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study.
    Saurat JH; Langley RG; Reich K; Unnebrink K; Sasso EH; Kampman W
    Br J Dermatol; 2011 Aug; 165(2):399-406. PubMed ID: 21564071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study.
    Ranjan N; Sharma NL; Shanker V; Mahajan VK; Tegta GR
    J Dermatolog Treat; 2007; 18(5):295-300. PubMed ID: 17852635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of weekly azathioprine pulse in the treatment of chronic plaque psoriasis: an open-label study.
    Verma P; Verma KK; Khanna N; Gupta S; Bhari N
    Clin Exp Dermatol; 2016 Oct; 41(7):717-22. PubMed ID: 27663145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis.
    Attwa EM; Elkot RA; Abdelshafey AS; Hafez AR
    Dermatol Ther; 2019 Sep; 32(5):e13051. PubMed ID: 31381231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial.
    Lajevardi V; Hallaji Z; Daklan S; Abedini R; Goodarzi A; Abdolreza M
    Int J Dermatol; 2015 Jan; 54(1):95-101. PubMed ID: 25209868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azathioprine weekly pulse versus methotrexate for the treatment of chronic plaque psoriasis: A randomized controlled trial.
    Verma KK; Kumar P; Bhari N; Gupta S; Kalaivani M
    Indian J Dermatol Venereol Leprol; 2021 [SEASON]; 87(4):509-514. PubMed ID: 33871211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate-betamethasone weekly oral pulse in psoriasis.
    Gupta R; Gupta S
    J Dermatolog Treat; 2007; 18(5):291-4. PubMed ID: 17852636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.
    Yoon HS; Youn JI
    J Dermatolog Treat; 2007; 18(5):286-90. PubMed ID: 17852632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study.
    Janagond AB; Kanwar AJ; Handa S
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e384-9. PubMed ID: 23066720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India.
    Kaur I; Dogra S; De D; Kanwar AJ
    Pediatr Dermatol; 2008; 25(2):184-8. PubMed ID: 18429775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Paul C; Kragballe K; Luger T; Lambert J; Chimenti S; Girolomoni G; Nicolas JF; Rizova E; Brunori M; Mistry S; Bergmans P; Barker J;
    Br J Dermatol; 2014 Feb; 170(2):435-44. PubMed ID: 24116868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.